Martin H Steinberg

List of Publications by Year
in descending order

377 papers	24,184 citations	14124 69 h-index	10129 145 g-index
389 all docs	389 docs citations	389 times ranked	16642 citing authors

#	Article	IF	Citations
1	Pharmacologic induction of PGC â€1Î± stimulates fetal haemoglobin gene expression. British Journal of Haematology, 2022, , .	1.2	4
2	Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. Expert Review of Hematology, 2022, 15, 117-125.	1.0	7
3	Fetal-like Hemoglobin in Sickle Cell Anemia. New England Journal of Medicine, 2022, 386, 689-691.	13.9	4
4	Fetal hemoglobin in Î² hemoglobinopathies: Is enough too much?. American Journal of Hematology, 2022, 97, 676-678.	2.0	2
5	Fetal hemoglobin modulates neurocognitive performance in sickle cell anemiaâœ°,âœ°âœ°. Current Research in Translational Medicine, 2022, 70, 103335.	1.2	3
6	Targeting fetal hemoglobin expression to treat Î² hemoglobinopathies. Expert Opinion on Therapeutic Targets, 2022, 26, 347-359.	1.5	7
7	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î²-Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	13.9	939
8	Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features. American Journal of Hematology, 2021, 96, E117-E121.	2.0	6
9	Update on Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia. Current Geriatrics Reports, 2021, 10, 51.	1.1	1
10	Exome sequencing in high and low fetal haemoglobin Arabâ€“Indian haplotype sickle cell disease. British Journal of Haematology, 2021, 194, e61-e64.	1.2	2
11	HbA 2 induction: the merit of pancellularity in sickle cell disease. British Journal of Haematology, 2021, 193, 1032-1033.	1.2	5
12	Strategies to improve pharmacogenomic-guided treatment options for patients with Î²-hemoglobinopathies. Expert Review of Hematology, 2021, 14, 1-3.	1.0	0
13	Treating sickle cell anemia: A new era dawns. American Journal of Hematology, 2020, 95, 338-342.	2.0	15
14	Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes. Journal of Clinical Medicine, 2020, 9, 3782.	1.0	27
15	Fetal hemoglobin in sickle cell anemia. Blood, 2020, 136, 2392-2400.	0.6	43
16	Prevalence and Diversity of Haplotypes of Sickle Cell Disease in the Eastern Province of Saudi Arabia. Hemoglobin, 2020, 44, 78-81.	0.4	16
17	Haptoglobin genotype predicts severe acute vasoâ€occlusive pain episodes in children with sickle cell anemia. American Journal of Hematology, 2020, 95, E92-E95.	2.0	7
18	Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program. Stem Cell Research, 2020, 46, 101803.	0.3	10

#	Article	IF	Citations
19	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent Î²-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. Blood, 2020, 136, 3-4.	0.6	34
20	Sickle cell anemia: HBB haplotypes; clinical heterogeneity; iPSC modeling. , 2020, , 29-45.		0
21	Sickle cell disease in the era of precision medicine: looking to the future. Expert Review of Precision Medicine and Drug Development, 2019, 4, 357-367.	0.4	7
22	â€œSicklingâ€•in vertebrates: Animal studies vs. sickle cell disease. Blood Reviews, 2019, 36, 88-94.	2.8	1
23	Primary polymerization prevention. Blood, 2019, 133, 1797-1798.	0.6	3
24	Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. Blood, 2019, 133, 2455-2459.	0.6	10
25	Haemolysis in sickle cell anaemia: effects of polymorphisms in Î±â€globin gene regulatory elements. British Journal of Haematology, 2019, 186, 363-364.	1.2	3
26	Recapitulating Hematopoietic Development in aÂDish. Current Human Cell Research and Applications, 2019, , 45-71.	0.1	1
27	BCL2L1 is associated with Î³-globin gene expression. Blood Advances, 2019, 3, 2995-3001.	2.5	11
28	A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells, Molecules, and Diseases, 2018, 69, 1-9.	0.6	45
29	A Mild Phenotype of Severe Î²+ Thalassemia in a 16-Month-Old Boy. Journal of Pediatric Hematology/Oncology, 2018, 40, e145-e147.	0.3	0
30	Notch and Aryl Hydrocarbon Receptor Signaling Impact Definitive Hematopoiesis from Human Pluripotent Stem Cells. Stem Cells, 2018, 36, 1004-1019.	1.4	36
31	A variant Sp1 (R218Q) transcription factor might enhance HbF expression in Î²⁰â€thalassaemia homozygotes. British Journal of Haematology, 2018, 180, 755-757.	1.2	0
32	Airlie House legend. American Journal of Hematology, 2018, 93, 1566-1567.	2.0	0
33	Induced pluripotent stem cellâ€“based mapping of Î²-globin expression throughout human erythropoietic development. Blood Advances, 2018, 2, 1998-2011.	2.5	20
34	Biomarker signatures of sickle cell disease severity. Blood Cells, Molecules, and Diseases, 2018, 72, 1-9.	0.6	22
35	A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells. Stem Cell Reports, 2017, 8, 1076-1085.	2.3	45
36	Go with the Flow. New England Journal of Medicine, 2017, 376, 485-487.	13.9	2

#	Article	IF	Citations
37	Genetic modulation of fetal hemoglobin in hydroxyureaâ€treated sickle cell anemia. American Journal of Hematology, 2017, 92, E70-E72.	2.0	9
38	Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 1561-1573.	13.9	898
39	Genetic determinants of HbF in Saudi Arabian and African Benin haplotype sickle cell anemia. American Journal of Hematology, 2017, 92, E555-E557.	2.0	10
40	Fetal hemoglobin in sickle cell anemia: The Arabâ€Indian haplotype and new therapeutic agents. American Journal of Hematology, 2017, 92, 1233-1242.	2.0	23
41	SIRT1 activates the expression of fetal hemoglobin genes. American Journal of Hematology, 2017, 92, 1177-1186.	2.0	23
42	Effects of hydroxyurea on Fâ€cells in sickle cell disease and potential impact of a second fetal globin inducer. American Journal of Hematology, 2017, 92, E10-E11.	2.0	7
43	Existence of HbF Enhancer Haplotypes atHBS1L-MYBIntergenic Region in Transfusion-Dependent SaudiÎ²-Thalassemia Patients. BioMed Research International, 2017, 2017, 1-7.	0.9	10
44	A phased SNP-based classification of sickle cell anemia HBB haplotypes. BMC Genomics, 2017, 18, 608.	1.2	31
45	Intravascular hemolysis and the pathophysiology of sickle cell disease. Journal of Clinical Investigation, 2017, 127, 750-760.	3.9	435
46	Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia. Blood, 2017, 130, 686-688.	0.6	19
47	Induced Pluripotent Stem Cell (iPSC)-Based Mapping of Globin Expression throughout Human Erythropoietic Development. Blood, 2017, 130, 946-946.	0.6	1
48	In Vivo Effects of LSD1 Inhibition By Small Chemical Inhibitors in Sickle Cell Mice. Blood, 2017, 130, 968-968.	0.6	0
49	The genetic basis of asymptomatic codon 8 frameâ€shift (<scp>HBB</scp>:c25_26del<scp>AA</scp>) Î²⁰â€thalassaemia homozygotes. British Journal of Haematology, 2016, 172, 958-965.	1.2	4
50	Learning Bayesian Networks from Correlated Data. Scientific Reports, 2016, 6, 25156.	1.6	16
51	Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease. Experimental Biology and Medicine, 2016, 241, 706-718.	1.1	21
52	Overview of Sickle Cell Anemia Pathophysiology. , 2016, , 49-73.		14
53	Variants of ZBTB7A (LRF) and its Î²-globin gene cluster binding motifs in sickle cell anemia. Blood Cells, Molecules, and Diseases, 2016, 59, 49-51.	0.6	11
54	A candidate transacting modulator of fetal hemoglobin gene expression in the Arabâ€"Indian haplotype of sickle cell anemia. American Journal of Hematology, 2016, 91, 1118-1122.	2.0	16

#	Article	IF	Citations
55	Homozygosity for a haplotype in the HBG2â€OR51B4 region is exclusive to Arabâ€Indian haplotype sickle cell anemia. American Journal of Hematology, 2016, 91, E308-11.	2.0	13
56	Sickle Cell Disease and Stroke. , 2016, , 439-467.		0
57	Isnâ€™t Your Staff Trained To Manage My Mother?. American Journal of Psychiatry, 2016, 173, 205-207.	4.0	3
58	Minireview: Genetic basis of heterogeneity and severity in sickle cell disease. Experimental Biology and Medicine, 2016, 241, 689-696.	1.1	87
59	Hereditary Persistence of Fetal Hemoglobin Caused by Single Nucleotide Promoter Mutations in Sickle Cell Trait and Hb SC Disease. Hemoglobin, 2016, 40, 64-65.	0.4	5
60	Bayesian Polynomial Regression Models to Fit Multiple Genetic Models for Quantitative Traits. Bayesian Analysis, 2015, 10, 53-74.	1.6	6
61	How we prevent and manage infection in sickle cell disease. British Journal of Haematology, 2015, 170, 757-767.	1.2	25
62	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait. Circulation, 2015, 132, e343-5.	1.6	11
63	HbA₂: biology, clinical relevance and a possible target for ameliorating sickle cell disease. British Journal of Haematology, 2015, 170, 781-787.	1.2	32
64	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. Human Genetics, 2015, 134, 895-904.	1.8	20
65	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: SickleÂCell Trait. Journal of the American College of Cardiology, 2015, 66, 2444-2446.	1.2	12
66	Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimerâ€™s Dementia and Death: The Cache County Dementia Progression Study. American Journal of Psychiatry, 2015, 172, 460-465.	4.0	249
67	Co-inheritance of novel ATRX gene mutation and globin (Î± & Î²) gene mutations in transfusion dependent beta-thalassemia patients. Blood Cells, Molecules, and Diseases, 2015, 55, 27-29.	0.6	15
68	Evaluation of an ensemble of genetic models for prediction of a quantitative trait. Frontiers in Genetics, 2015, 5, 474.	1.1	1
69	Genomic approaches to identifying targets for treating β2 hemoglobinopathies. BMC Medical Genomics, 2015, 8, 44.	0.7	22
70	A Library of Sickle Cell Anemia Induced Pluripotent Stem Cells of Diverse Haplotypes and Ethnicities. Blood, 2015, 126, 2354-2354.	0.6	0
71	Association of FOXO3A Polymorphisms with Hematocrit, LDH and Longevity in Patients with Sickle Cell Anemia from CSSCD, Walk-Phasst, and PUSH Clinical Trials. Blood, 2015, 126, 2176-2176.	0.6	0
72	Polymorphisms Associated with the Arab-Indian Haplotype of Sickle Cell Anemia Are Candidate Fetal Hemoglobin Gene Modulators. Blood, 2015, 126, 3388-3388.	0.6	0

#	Article	IF	Citations
73	A Candidate Trans-Acting Modulator of Fetal Hemoglobin Gene Expression in the Arab-Indian Haplotype of Sickle Cell Anemia. Blood, 2015, 126, 409-409.	0.6	0
74	Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 238-240.	2.5	1
75	Nitric oxide-based treatment for sickle cell leg ulcers?. Lancet Haematology,the, 2014, 1, e86-e87.	2.2	6
76	A GCH1 haplotype confers sexâ€specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. American Journal of Hematology, 2014, 89, 187-193.	2.0	38
77	Sickle cell disease in <scp>S</scp>audi <scp>A</scp>rabia: the phenotype in adults with the <scp>A</scp>rabâ€<scp>I</scp>ndian haplotype is not benign. British Journal of Haematology, 2014, 164, 597-604.	1.2	72
78	Hypoxic Response Contributes to Altered Gene Expression and Precapillary Pulmonary Hypertension in Patients With Sickle Cell Disease. Circulation, 2014, 129, 1650-1658.	1.6	32
79	Prediction of Fetal Hemoglobin in Sickle Cell Anemia Using an Ensemble of Genetic Risk Prediction Models. Circulation: Cardiovascular Genetics, 2014, 7, 110-115.	5.1	27
80	Quantification of <scp>HBG</scp> m<scp>RNA</scp> in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and betaâ€thalassemia. European Journal of Haematology, 2014, 92, 66-72.	1.1	18
81	Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. International Journal of Geriatric Psychiatry, 2014, 29, 153-159.	1.3	44
82	A novel HBA2 gene conversion in cis or trans: â€œÎ±12 alleleâ€•in a Saudi population. Blood Cells, Molecules, and Diseases, 2014, 53, 199-203.	0.6	23
83	More Blood for Sickle Cell Anemia?. New England Journal of Medicine, 2014, 371, 775-776.	13.9	9
84	The genetics of hemoglobin A₂ regulation in sickle cell anemia. American Journal of Hematology, 2014, 89, 1019-1023.	2.0	20
85	Fetal hemoglobin in sickle cell anemia: a glass half full?. Blood, 2014, 123, 481-485.	0.6	181
86	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197
87	Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells, Molecules, and Diseases, 2014, 53, 265-271.	0.6	17
88	Quantitative Magnetic Resonance Imaging Analysis of the Lacrimal Gland in Sickle Cell Disease. Journal of Computer Assisted Tomography, 2014, 38, 674-680.	0.5	8
89	Genes Associated with Alloimmunization to Blood Group Antigens in Sickle Cell Disease. Blood, 2014, 124, 762-762.	0.6	3
90	Sickle Cell Disease and Stroke. , 2014, , 1-35.		0

#	Article	IF	Citations
91	BCL11A enhancer Haplotypes Are Associated with the Distribution of HbF in Arab-Indian and African Haplotype Sickle Cell Anemia but Not the Different Population Levels of HbF. Blood, 2014, 124, 4066-4066.	0.6	0
92	Genetic studies of fetal hemoglobin in the Arabâ€Indian haplotype sickle cellâ€Î²⁰ thalassemia. American Journal of Hematology, 2013, 88, 531-532.	2.0	8
93	Genetic modulation of HbF in Brazilians with HbSC disease and sickle cell anemia. American Journal of Hematology, 2013, 88, 923-924.	2.0	5
94	Fetal hemoglobin in sickle cell anemia: Genetic studies of the Arab-Indian haplotype. Blood Cells, Molecules, and Diseases, 2013, 51, 22-26.	0.6	50
95	qMRI relaxometry of mandibular bone marrow: A monomodal distribution in sickle cell disease. Journal of Magnetic Resonance Imaging, 2013, 37, 1182-1188.	1.9	9
96	Genetic determinants of haemolysis in sickle cell anaemia. British Journal of Haematology, 2013, 161, 270-278.	1.2	45
97	The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood, 2013, 122, 376-385.	0.6	119
98	Cerebrovascular events in sickle cellâ€beta thalassemia treated with hydroxyurea: A single center prospective survey in adult Italians. American Journal of Hematology, 2013, 88, E261-4.	2.0	18
99	HbC disorders. Blood, 2013, 122, 3698-3698.	0.6	3
100	Craniofacial Bone Infarcts in Sickle Cell Disease. Journal of Computer Assisted Tomography, 2013, 37, 91-97.	0.5	20
101	Genome-Wide Meta-Analysis of Systolic Blood Pressure in Children with Sickle Cell Disease. PLoS ONE, 2013, 8, e74193.	1.1	21
102	Neonatal Hemolytic Anemia and (Î²)0-Thalassemia Caused By Novel Deletions Involving The Î²-Globin Gene Cluster. Blood, 2013, 122, 3452-3452.	0.6	1
103	The Evolutionary Impact Of Malaria On The Saudi Arabian Genome. Blood, 2013, 122, 1001-1001.	0.6	1
104	Fetal Hemoglobin In Sickle Cell Anemia: A Glass Half Full?. Blood, 2013, 122, 4691-4691.	0.6	0
105	Genetic Association Of a MAPK8 Expression Quantitative Trait Locus With Pre-Capillary Pulmonary Hypertension In Sickle Cell Disease. Blood, 2013, 122, 991-991.	0.6	0
106	Patients Homozygous For Codon 8 (â€“AA) Frame-Shift Î²0-Thalassemia Mutation With Markedly Increased HbF. Blood, 2013, 122, 3455-3455.	0.6	0
107	Identification Of Protein and Post Translational Modification Markers Of Pulmonary Vasculopathy In Sickle Cell Disease. Blood, 2013, 122, 2233-2233.	0.6	2
108	Sickle Cell Disease and Other Hemoglobinopathies. , 2012, , 1066-1075.		4

#	Article	IF	Citations
109	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood, 2012, 120, 1961-1962.	0.6	73
110	Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns. American Journal of Psychiatry, 2012, 169, 900-906.	4.0	171
111	Genetic Signatures of Exceptional Longevity in Humans. PLoS ONE, 2012, 7, e29848.	1.1	340
112	A Genome-Wide Association Study of Total Bilirubin and Cholelithiasis Risk in Sickle Cell Anemia. PLoS ONE, 2012, 7, e34741.	1.1	55
113	Bayesian Methods for Multivariate Modeling of Pleiotropic SNP Associations and Genetic Risk Prediction. Frontiers in Genetics, 2012, 3, 176.	1.1	28
114	Severe fetal and neonatal hemolytic anemia due to a 198â€‰kb deletion removing the complete Î²â€globin gene cluster. Pediatric Blood and Cancer, 2012, 59, 941-944.	0.8	11
115	Genetic modifiers of sickle cell disease. American Journal of Hematology, 2012, 87, 795-803.	2.0	218
116	A functional promoter polymorphism of the Î´-globin gene is a specific marker of the Arab-Indian haplotype. American Journal of Hematology, 2012, 87, 824-826.	2.0	11
117	Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. British Journal of Haematology, 2012, 156, 259-264.	1.2	97
118	Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF-ÎºB signaling pathway. Molecular Immunology, 2012, 50, 117-123.	1.0	26
119	Is HbA2 level a reliable diagnostic measurement for Î²-thalassemia trait in people with iron deficiency?. American Journal of Hematology, 2012, 87, 114-116.	2.0	26
120	Fetal hemoglobin in sickle cell anemia: Molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. American Journal of Hematology, 2012, 87, 217-219.	2.0	30
121	Framing the research agenda for sickle cell trait: Building on the current understanding of clinical events and their potential implications. American Journal of Hematology, 2012, 87, 340-346.	2.0	72
122	Severe Impairment of Î³-Globin Gene Silencing in an Asymptomatic Adult Patient Homozygous for the Codon 8 (â€“AA) Frame-Shift Î²0-Thalassemia Mutation. Blood, 2012, 120, 1022-1022.	0.6	0
123	Prediction of Fetal Hemoglobin in Sickle Cell Anemia Using a Genetic Risk Score. Blood, 2012, 120, 3216-3216.	0.6	0
124	Induced Pluripotent Stem Cell Modeling of Sickle Cell Anemia. Blood, 2012, 120, 3233-3233.	0.6	0
125	Genetic Determinants of Hemolysis in Sickle Cell Anemia.. Blood, 2012, 120, 2104-2104.	0.6	0
126	The Aryl Hydrocarbon Receptor (AhR) Regulates the Production of Bipotential Hematopoietic Progenitor Cells. Blood, 2012, 120, 766-766.	0.6	1

#	Article	IF	Citations
127	Progression of Cognitive, Functional, and Neuropsychiatric Symptom Domains in a Population Cohort With Alzheimer Dementia: The Cache County Dementia Progression Study. American Journal of Geriatric Psychiatry, 2011, 19, 532-542.	0.6	198
128	A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood, 2011, 117, 4935-4945.	0.6	116
129	Ancestry of African Americans with sickle cell disease. Blood Cells, Molecules, and Diseases, 2011, 47, 41-45.	0.6	35
130	Fetal hemoglobin in sickle cell anemia. Blood, 2011, 118, 19-27.	0.6	392
131	Response: genetic admixture in sickle cell disease. Blood, 2011, 118, 4495-4495.	0.6	2
132	The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multiâ€centre CHAMPS trial. British Journal of Haematology, 2011, 152, 771-776.	1.2	30
133	Senicapoc trial results support the existence of different subâ€phenotypes of sickle cell disease with possible drugâ€induced phenotypic shifts. British Journal of Haematology, 2011, 155, 636-638.	1.2	13
134	The Association Between Hydroxyurea Treatment and Pain Intensity, Analgesic Use, and Utilization in Ambulatory Sickle Cell Anemia Patients. Pain Medicine, 2011, 12, 697-705.	0.9	31
135	Severe sickle cell anemia is associated with increased plasma levels of TNFâ€R1 and VCAMâ€1. American Journal of Hematology, 2011, 86, 220-223.	2.0	34
136	G6PD deficiency and stroke in the CSSCD. American Journal of Hematology, 2011, 86, 331-331.	2.0	25
137	Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. American Journal of Hematology, 2011, 86, 612-614.	2.0	30
138	Sickle Cell Disease. Annals of Internal Medicine, 2011, 155, ITC3.	2.0	25
139	Whole Genome Sequences of a Male and Female Supercentenarian, Ages Greater than 114â€‰Years. Frontiers in Genetics, 2011, 2, 90.	1.1	51
140	Co-Inheritance of Delta Thalassemia Might Contribute to the High Fetal Hemoglobin in Sickle Cell Anemia Patients with the Saudi-Indian Haplotype. Blood, 2011, 118, 1056-1056.	0.6	1
141	Clinical and Genetic Variability of Red Blood Cell Hemolysis in Sickle Cell Anemia. Blood, 2011, 118, 1077-1077.	0.6	6
142	An Elevated Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease Is Associated with Polymorphisms in Genes Impacting Innate Immunity. Blood, 2011, 118, 514-514.	0.6	0
143	Genetic modifiers of the severity of sickle cell anemia identified through a genomeâ€wide association study. American Journal of Hematology, 2010, 85, 29-35.	2.0	83
144	Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5â€² olfactory receptor gene cluster. Blood, 2010, 115, 1815-1822.	0.6	146

#	Article	IF	Citations
145	Pulmonary hypertension and NO in sickle cell. Blood, 2010, 116, 852-854.	0.6	59
146	Genetic Signatures of Exceptional Longevity in Humans. Science, 2010, 329, .	6.0	95
147	The risks and benefits of longâ€term use of hydroxyurea in sickle cell anemia: A 17.5 year followâ€up. American Journal of Hematology, 2010, 85, 403-408.	2.0	385
148	Unexpectedly low pulse oximetry measurements associated with variant hemoglobins: A systematic review. American Journal of Hematology, 2010, 85, 882-885.	2.0	72
149	Clustering by genetic ancestry using genome-wide SNP data. BMC Genetics, 2010, 11, 108.	2.7	40
150	Variability In Hb A2 levels among Individuals with Beta-Thalassemia Trait: Is Iron Deficiency Associated with Abnormally Low Hb A2?. Blood, 2010, 116, 4281-4281.	0.6	1
151	Alterations In HLA-DR Expression In Peripheral Blood Mononuclear Cells Are Associated with An Elevated Tricuspid Regurgitant Jet Velocity and Pulmonary Hypertension of Sickle Cell Disease. Blood, 2010, 116, 2640-2640.	0.6	0
152	Severe Fetal and Neonatal Anemia Due to Heterozygosity for a 198 Kb Deletion Removing the Entire Î²-Globin Gene Cluster. Blood, 2010, 116, 5171-5171.	0.6	0
153	Tumor Necrosis Factor-Î± Signaling In Sickle Cell Disease: Elevated Biomarker Levels and Genetic Associations with Disease Severity. Blood, 2010, 116, 2654-2654.	0.6	0
154	Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of Saudi Patients From the Eastern Province. Blood, 2010, 116, 1627-1627.	0.6	0
155	A 3-Bp Deletion Between Transcription Factor Binding Motifs In the HBS1L-MYB Intergenic Region on Chromosome 6q23 Is Associated with HbF Expression. Blood, 2010, 116, 1013-1013.	0.6	1
156	Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of the High Fetal Hemoglobin Phenotype In African American Patients. Blood, 2010, 116, 2068-2068.	0.6	0
157	Characterization of HbF Decline In Compound Heterozygotes for HbS and Deletional Hereditary Persistence of Fetal Hemoglobin. Blood, 2010, 116, 1626-1626.	0.6	2
158	The Erythrocyte Membrane. , 2009, , 158-184.		3
159	The Molecular Basis of Î± Thalassemia. , 2009, , 241-265.		1
160	Nuclear Factors That Regulate Erythropoiesis. , 2009, , 62-85.		3
161	Rheology and Vascular Pathobiology in Sickle Cell Disease and Thalassemia. , 2009, , 139-157.		1
162	Novel Approaches to Treatment. , 2009, , 755-773.		0

#	Article	IF	Citations
163	THE Î² THALASSEMIAS. , 2009, , 321-322.		0
164	Clinical Aspects of Î² Thalassemia and Related Disorders. , 2009, , 357-416.		10
165	THE MOLECULAR, CELLULAR, AND GENETIC BASIS OF HEMOGLOBIN DISORDERS. , 2009, , 1-2.		0
166	Genetic Etiologies for Phenotypic Diversity in Sickle Cell Anemia. Scientific World Journal, The, 2009, 9, 46-67.	0.8	146
167	Mechanisms and Clinical Complications of Hemolysis in Sickle Cell Disease and Thalassemia. , 2009, , 201-224.		9
168	RNA Editing Genes Associated with Extreme Old Age in Humans and with Lifespan in C. elegans. PLoS ONE, 2009, 4, e8210.	1.1	81
169	The Molecular Basis of Î² Thalassemia, ÎÎ² Thalassemia, and Hereditary Persistence of Fetal Hemoglobin. , 2009, , 323-356.		34
170	Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain, 2009, 146, 91-98.	2.0	43
171	Evidence of Hyposplenism in the Presence of Splenomegaly. Scandinavian Journal of Haematology, 2009, 31, 437-439.	0.0	13
172	Hemoglobin Kenya composed of Î±â€•and (^AÎ³Î²)â€fusionâ€globin chains, associated with hereditary persistence of fetal hemoglobin. American Journal of Hematology, 2009, 84, 55-58.	2.0	10
173	Genomeâ€wide association studies and the genetic dissection of complex traits. American Journal of Hematology, 2009, 84, 504-515.	2.0	64
174	Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients. American Journal of Hematology, 2009, 84, 603-606.	2.0	15
175	Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: Differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine, 2009, 46, 72-78.	1.4	9
176	BCL11A represses HBG transcription in K562 cells. Blood Cells, Molecules, and Diseases, 2009, 42, 144-149.	0.6	60
177	Clinical and Pathophysiological Aspects of Sickle Cell Anemia. , 2009, , 437-496.		3
178	Genetic Modulation of Sickle Cell Disease and Thalassemia. , 2009, , 638-657.		4
179	Sickle Cell Trait. , 2009, , 549-563.		0
180	SPECIAL TOPICS IN HEMOGLOBINOPATHIES. , 2009, , 623-624.		0

#	Article	IF	Citations
181	NEW APPROACHES TO THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASSEMIA. , 2009, , 687-688.		0
182	Hemoglobins of the Embryo, Fetus, and Adult. , 2009, , 119-136.		10
183	Hemoglobin SE Disease in Maine, and Severe Thalassemia in New Hampshire. Journal of Pediatric Hematology/Oncology, 2009, 31, 307.	0.3	5
184	Genome-Wide Association Study of Stroke in Sickle Cell Anemia.. Blood, 2009, 114, 1528-1528.	0.6	18
185	A GCH1 Haplotype Associated with Susceptibility to Vasoocclusive Pain and Impaired Vascular Function in Sickle Cell Anemia.. Blood, 2009, 114, 575-575.	0.6	5
186	Genome-Wide Studies in Sickle Cell Anemia Show Associations Between SNPs in the Olfactory Receptor Gene Cluster and Fetal Hemoglobin Concentration.. Blood, 2009, 114, 821-821.	0.6	2
187	A hierarchical and modular approach to the discovery of robust associations in genome-wide association studies from pooled DNA samples. BMC Genetics, 2008, 9, 6.	2.7	26
188	Imputation of missing genotypes: an empirical evaluation of IMPUTE. BMC Genetics, 2008, 9, 85.	2.7	31
189	Point and 5â€year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 2008, 23, 170-177.	1.3	579
190	Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigm. American Journal of Hematology, 2008, 83, 1-3.	2.0	20
191	Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations. American Journal of Hematology, 2008, 83, 189-195.	2.0	34
192	Sickle cell bone disease: Response to vitamin D and calcium. American Journal of Hematology, 2008, 83, 271-274.	2.0	68
193	Variation and heritability of Hb F and Fâ€cells among Î²â€thalassemia heterozygotes in Hong Kong. American Journal of Hematology, 2008, 83, 458-464.	2.0	30
194	Pulmonary arterial hypertension and leftâ€sided heart disease in sickle cell disease: Clinical characteristics and association with soluble adhesion molecule expression. American Journal of Hematology, 2008, 83, 547-553.	2.0	58
195	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood, 2008, 111, 402-410.	0.6	157
196	Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a caseâ€crossover study. British Journal of Haematology, 2008, 143, 433-438.	1.2	52
197	BCL11A is a major HbF quantitative trait locus in three different populations with Î²-hemoglobinopathies. Blood Cells, Molecules, and Diseases, 2008, 41, 255-258.	0.6	158
198	A T-to-G Transversion at Nucleotide â^'567 Upstream of HBG2 in a GATA-1 Binding Motif Is Associated with Elevated Hemoglobin F. Molecular and Cellular Biology, 2008, 28, 4386-4393.	1.1	39

#	Article	IF	Citations
199	Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. International Psychogeriatrics, 2008, 20, 538-53.	0.6	64
200	SNPing away at sickle cell pathophysiology. Blood, 2008, 111, 5420-5421.	0.6	5
201	Sickle Cell Anemia, the First Molecular Disease: Overview of Molecular Etiology, Pathophysiology, and Therapeutic Approaches. Scientific World Journal, The, 2008, 8, 1295-1324.	0.8	184
202	Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain. PLoS ONE, 2008, 3, e2095.	1.1	152
203	Fetal Hemoglobin in Sickle Cell Anemia: A Genome-Wide Association Study of the Response to Hydroxyurea. Blood, 2008, 112, 2471-2471.	0.6	1
204	Pneumococcus and Sickle Cell Disease: The Beginning of the End?. Clinical Infectious Diseases, 2007, 44, 1434-1435.	2.9	6
205	Two New Î±-Thalassemia Frameshift Mutations. Hemoglobin, 2007, 31, 135-139.	0.4	9
206	A network model to predict the risk of death in sickle cell disease. Blood, 2007, 110, 2727-2735.	0.6	159
207	Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics Journal, 2007, 7, 386-394.	0.9	109
208	Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. American Journal of Hematology, 2007, 82, 179-184.	2.0	48
209	Hemoglobin SE diseaseâ€"A concise review. American Journal of Hematology, 2007, 82, 643-649.	2.0	46
210	Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 2007, 21, 37-47.	2.8	728
211	Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Rapid Communications in Mass Spectrometry, 2007, 21, 2195-2203.	0.7	28
212	Sickle cell disease due to compound heterozygosity for Hb S and a novel 7.7-kb ?-globin gene deletion. European Journal of Haematology, 2007, 78, 82-85.	1.1	11
213	A Repertoire of Genes Modifying the Risk of Death in Sickle Cell Anemia.. Blood, 2007, 110, 150-150.	0.6	6
214	Association of Genetic Polymorphisms in the TGF-Î² Pathway with the Acute Chest Syndrome of Sickle Cell Anemia.. Blood, 2007, 110, 2247-2247.	0.6	8
215	Effectiveness of a dedicated day hospital for management of acute sickle cell pain. Haematologica, 2007, 92, 854-854.	1.7	36
216	Low Erythrocyte Glutamine-to-Glutamate Ratio: A Novel Biomarker of Hemolysis and Pulmonary Hypertension in Sickle Cell Disease.. Blood, 2007, 110, 2257-2257.	0.6	0

#	Article	IF	Citations
217	Predicting Acute Chest Syndrome in Sickle Cell Disease Patients Hospitalized for Acute Vasoocclusive Events.. Blood, 2007, 110, 3390-3390.	0.6	2
218	Association of Wind Speed and the Occurrence of Sickle Cell Acute Painful Episodes: Results of a Case-Crossover Study.. Blood, 2007, 110, 3402-3402.	0.6	0
219	Regulators of Erythrocyte Volume as Modifiers in Sickle Cell Disease: The Gardos Channel.. Blood, 2007, 110, 3387-3387.	0.6	6
220	Pathophysiologically based drug treatment of sickle cell disease. Trends in Pharmacological Sciences, 2006, 27, 204-210.	4.0	77
221	Screening and counseling for thalassemia. Blood, 2006, 107, 1735-1737.	0.6	9
222	N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2006, 296, 310.	3.8	169
223	Modifier genes and sickle cell anemia. Current Opinion in Hematology, 2006, 13, 131-136.	1.2	76
224	Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. British Journal of Haematology, 2006, 133, 570-578.	1.2	155
225	Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. International Journal of Geriatric Psychiatry, 2006, 21, 930-936.	1.3	36
226	Hemoglobinopathies mimicking Hb SÎ²-thalassemia: Hb S/S with Î±-thalassemia and Hb S/Volga. American Journal of Hematology, 2006, 81, 361-365.	2.0	10
227	Lacrimal gland enlargement in sickle cell disease. American Journal of Hematology, 2006, 81, 888-889.	2.0	12
228	Abnormal Pulmonary Function in Adults with Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1264-1269.	2.5	177
229	Association of Polymorphisms ofIGF1Rand Genes in the Transforming Growth Factorâ€“Î²/Bone Morphogenetic Protein Pathway with Bacteremia in Sickle Cell Anemia. Clinical Infectious Diseases, 2006, 43, 593-598.	2.9	54
230	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. Blood, 2006, 108, 1208-1208.	0.6	7
231	The Hyperhemolysis Phenotype in Sickle Cell Anemia: Increased Risk of Leg Ulcers, Priapism, Pulmonary Hypertension and Death with Decreased Risk of Vasoocclusive Events.. Blood, 2006, 108, 787-787.	0.6	4
232	Fetal Hemoglobin (HbF) in Sickle Cell Anemia: Genome-Wide Association Studies Using Pooled DNA Samples Can Reveal Genetic Associations with HbF Concentration.. Blood, 2006, 108, 1221-1221.	0.6	0
233	Identification of Oxidative Post-Translational Modifications on Plasma Albumin in Patients with Pulmonary Hypertension of Sickle Cell Anemia.. Blood, 2006, 108, 1215-1215.	0.6	0
234	Long-Term Vitamin D Supplementation Improves Bone Mineral Density (BMD) in Patients with Sickle Cell Disease.. Blood, 2006, 108, 3800-3800.	0.6	1

#	Article	IF	Citations
235	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. Blood, 2006, 108, 788-788.	0.6	1
236	Fetal Hemoglobin in Sickle Cell Anemia: Associations with Single Nucleotide Polymorphisms in Quantitative Trait Loci on Chromsomes 8q12 and Xp22.. Blood, 2006, 108, 1222-1222.	0.6	1
237	Severity of Sickle Cell Disease: Modeling Interrelationships among Hemolysis, Pulmonary Hypertension and Risk of Death.. Blood, 2006, 108, 786-786.	0.6	0
238	Sickle cell disease and hydroxyurea: the good, the bad, and the future. Blood, 2005, 105, 441-441.	0.6	2
239	Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood, 2005, 106, 372-375.	0.6	102
240	Patients with thalassemia in the United States. Blood, 2005, 105, 4896-4897.	0.6	5
241	Hemolysis-associated priapism in sickle cell disease. Blood, 2005, 106, 3264-3267.	0.6	183
242	Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. British Journal of Haematology, 2005, 128, 266-272.	1.2	71
243	Predicting clinical severity in sickle cell anaemia. British Journal of Haematology, 2005, 129, 465-481.	1.2	284
244	Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nature Genetics, 2005, 37, 435-440.	9.4	300
245	Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. American Journal of Hematology, 2005, 78, 240-242.	2.0	41
246	Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. Physiological Genomics, 2005, 21, 293-298.	1.0	19
247	Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia. JAMA - Journal of the American Medical Association, 2005, 293, 2211.	3.8	2
248	Creatinine Clearance in Sickle Cell Anemia Is Modulated by Genes in the TGF-Î²/BMP Pathway.. Blood, 2005, 106, 3175-3175.	0.6	11
249	Gene-Gene Interactions and the Pathophysiology of Sickle Cell Disease: Modeling the Effects of SNPs on Sickle Cell-Associated Vasoocclusive Events Using Classification and Regression Trees and Stochastic Gradient Boosting.. Blood, 2005, 106, 3183-3183.	0.6	18
250	Leg Ulcers in Sickle Cell Anemia Are Associated with Laboratory Markers of Hemolysis and SNPs in KL and Genes of the TGF-Î²/BMP Pathway.. Blood, 2005, 106, 2317-2317.	0.6	1
251	Polymorphisms (Snps) in Multiple Genes of the Tgf-ÃŸ/Bmp Pathway Are Associated with a Global Measure of Sickle Cell Disease Severity.. Blood, 2005, 106, 74-74.	0.6	0
252	Association of Polymorphisms of the Transforming Growth Factor-Î²/Bone Morphogenetic Protein (TGF-Î²/BMP) Pathway with Sickle Cell Bacteremia.. Blood, 2005, 106, 3170-3170.	0.6	0

#	Article	IF	Citations
253	Sickle Cell Disease. Hematology American Society of Hematology Education Program, 2004, 2004, 35-47.	0.9	82
254	Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature, 2004, 429, 75-79.	13.7	395
255	Hemoglobin Titusville, a low oxygen affinity variant hemoglobin, in a family of Northern European background. American Journal of Hematology, 2004, 77, 384-386.	2.0	31
256	The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 2004, 19, 19-26.	1.3	149
257	Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. International Journal of Geriatric Psychiatry, 2004, 19, 144-150.	1.3	18
258	Cognitive Response to Pharmacological Treatment for Depression in Alzheimer Disease: Secondary Outcomes From the Depression in Alzheimer's Disease Study (DIADS). American Journal of Geriatric Psychiatry, 2004, 12, 491-498.	0.6	29
259	Hb Hope [Î²136(H14)Glyâ†'Asp (GGTâ†'GAT)]: Interactions with Hb S [Î²6(A3)Gluâ†'Val (GAGâ†'GTG)], Other Variant Hemoglobins and Thalassemia. Hemoglobin, 2004, 28, 277-285.	0.4	11
260	A Novel Sickle Hemoglobin: Hemoglobin S-South End. Journal of Pediatric Hematology/Oncology, 2004, 26, 773-776.	0.3	18
261	Genetic Polymorphisms Associated with Fetal Hemoglobin Response to Hydroxyurea in Patients with Sickle Cell Anemia.. Blood, 2004, 104, 108-108.	0.6	6
262	Association of Single Nucleotide Polymorphisms in Klotho with Priapism in Sickle Cell Anemia.. Blood, 2004, 104, 1673-1673.	0.6	2
263	A Sickle Transgenic Mouse Model of Acute Chest Syndrome.. Blood, 2004, 104, 3585-3585.	0.6	0
264	Single Nucleotide Polymorphisms (SNPs) in Human Homologs of Genes Up-Regulated in the Kidney of S+Sâ^' Antilles Transgenic Mice.. Blood, 2004, 104, 3584-3584.	0.6	0
265	Multigenic Dissection and Prognostic Modeling of Overt Stroke in Sickle Cell Anemia.. Blood, 2004, 104, 1655-1655.	0.6	0
266	Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. American Journal of Hematology, 2003, 72, 121-126.	2.0	31
267	Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. American Journal of Hematology, 2003, 74, 104-111.	2.0	103
268	The paradox of hemoglobin SC disease. Blood Reviews, 2003, 17, 167-178.	2.8	212
269	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	3.8	741
270	Treating Depression in Alzheimer Disease. Archives of General Psychiatry, 2003, 60, 737.	13.8	361

#	Article	IF	Citations
271	Pathophysiological-Based Approaches to Treatment of Sickle Cell Disease. Annual Review of Medicine, 2003, 54, 89-112.	5.0	43
272	Therapies to increase fetal hemoglobin in sickle cell disease. Psychophysiology, 2003, 2, 95-101.	1.1	6
273	Developing treatment for sickle cell disease. Expert Opinion on Investigational Drugs, 2002, 11, 645-659.	1.9	3
274	Hydroxyurea Treatment for Sickle Cell Disease. Scientific World Journal, The, 2002, 2, 1706-1728.	0.8	18
275	Incidence, prevalence, and outcomes of depression in residents of a long-term care facility with dementia. International Journal of Geriatric Psychiatry, 2002, 17, 247-253.	1.3	107
276	Gene Expression Profiling during Erythroid Differentiation of K562 Cells. Blood Cells, Molecules, and Diseases, 2001, 27, 309-319.	0.6	4
277	Pathophysiology of sickle cell disease: Role of cellular and genetic modifiers. Seminars in Hematology, 2001, 38, 299-306.	1.8	103
278	MODULATION OF FETAL HEMOGLOBIN IN SICKLE CELL ANEMIA. Hemoglobin, 2001, 25, 195-211.	0.4	14
279	Pharmacologic Modulation of Fetal Hemoglobin. Medicine (United States), 2001, 80, 328-344.	0.4	57
280	Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. International Journal of Geriatric Psychiatry, 2001, 16, 1043-1053.	1.3	252
281	THALASSEMIA INTERMEDIA AND EXTRAMEDULLARY HEMATOPOIESIS ASSOCIATED WITH COMPOUND HETEROZYGOSITY FOR THE 532 BP DELETION OF THE Î²-GLOBIN GENE AND GENE DELETION HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN. Hemoglobin, 2001, 25, 91-96.	0.4	1
282	Role of Epistatic (Modifier) Genes in the Modulation of the Phenotypic Diversity of Sickle Cell Anemia. Fetal and Pediatric Pathology, 2001, 20, 123-136.	0.3	26
283	Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2099.	3.8	173
284	Pathophysiology of sickle cell disease: Role of cellular and genetic modifiers. Seminars in Hematology, 2001, 38, 299-306.	1.8	53
285	New Views of Sickle Cell Disease Pathophysiology and Treatment. Hematology American Society of Hematology Education Program, 2000, 2000, 2-17.	0.9	44
286	Maximum urine concentrating ability in children with Hb SC disease: Effects of hydroxyurea. , 2000, 64, 47-52.		25
287	Characteristics and outcomes of dementia residents in an assisted living facility. International Journal of Geriatric Psychiatry, 2000, 15, 586-593.	1.3	86
288	Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Sertraline in the Treatment of Depression Complicating Alzheimerâ€™s Disease: Initial Results From the Depression in Alzheimerâ€™s Disease Study. American Journal of Psychiatry, 2000, 157, 1686-1689.	4.0	185

#	Article	IF	Citations
289	Characteristics and outcomes of dementia residents in an assisted living facility. , 2000, 15, 586.		2
290	New Views of Sickle Cell Disease Pathophysiology and Treatment. Hematology American Society of Hematology Education Program, 2000, 2000, 2-17.	0.9	8
291	New Views of Sickle Cell Disease Pathophysiology and Treatment. Hematology American Society of Hematology Education Program, 2000, 2000, 2-17.	0.9	3
292	Southern Society for Clinical Investigation Founders Medal Recipient???s Address. American Journal of the Medical Sciences, 2000, 320, 161-162.	0.4	0
293	Sickle Cell Anemia as a Possible State of Enhanced Anti-Apoptotic Tone: Survival Effect of Vascular Endothelial Growth Factor on Circulating and Unanchored Endothelial Cells. Blood, 1999, 93, 3824-3830.	0.6	113
294	Physical Aggression in Dementia Patients and Its Relationship to Depression. American Journal of Psychiatry, 1999, 156, 66-71.	4.0	173
295	Novel approaches to treatment of sickle cell anaemia. Expert Opinion on Investigational Drugs, 1999, 8, 1823-1836.	1.9	0
296	Wandering behaviour in community-residing persons with dementia. , 1999, 14, 272-279.		107
297	Management of Sickle Cell Disease. New England Journal of Medicine, 1999, 340, 1021-1030.	13.9	557
298	Induction of Globin Synthesis in K562 Cells Is Associated with Differential Expression of Transcription Factor Genes. Blood Cells, Molecules, and Diseases, 1999, 25, 156-165.	0.6	13
299	The General Medical Health Rating: A Bedside Global Rating of Medical Comorbidity in Patients with Dementia. Journal of the American Geriatrics Society, 1999, 47, 487-491.	1.3	154
300	6 Pathophysiology of sickle cell disease. Best Practice and Research: Clinical Haematology, 1998, 11, 163-184.	1.1	65
301	Fetal Hemoglobin in Sickle Cell Anemia: Examination of Phylogenetically Conserved Sequences Within the Locus Control Region but Outside the Cores of Hypersensitive Sites 2 and 3. Blood Cells, Molecules, and Diseases, 1997, 23, 188-200.	0.6	14
302	Natural History of Blood Pressure in Sickle Cell Disease: Risks for Stroke and Death Associated with Relative Hypertension in Sickle Cell Anemia. American Journal of Medicine, 1997, 102, 171-177.	0.6	224
303	Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to Hydroxyurea. Blood, 1997, 89, 1078-1088.	0.6	368
304	RheothRx (Poloxamer 188) Injection for the Acute Painful Episode of Sickle Cell Disease: A Pilot Study. Blood, 1997, 90, 2041-2046.	0.6	106
305	Cellular effects of hydroxyurea in Hb SC disease. British Journal of Haematology, 1997, 98, 838-844.	1.2	62
306	Sickle Cell Disease: Present and Future Treatment. American Journal of the Medical Sciences, 1996, 312, 166-174.	0.4	9

#	Article	IF	Citations
307	Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive â€œSwitchingâ€•Agent. Medicine (United States), 1996, 75, 300-326.	0.4	294
308	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. , 1996, 51, 296-301.		83
309	Î²-Globin gene haplotype in Hb SC disease. , 1996, 52, 189-191.		16
310	Sickle Cell Disease: Present and Future Treatment. American Journal of the Medical Sciences, 1996, 312, 166-174.	0.4	17
311	Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. American Journal of Hematology, 1995, 48, 175-181.	2.0	120
312	Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia. American Journal of Hematology, 1995, 50, 140-143.	2.0	41
313	Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death. New England Journal of Medicine, 1994, 330, 1639-1644.	13.9	2,879
314	Sickle Cell Anemia and Fetal Hemoglobin. American Journal of the Medical Sciences, 1994, 308, 259-265.	0.4	11
315	DNA diagnosis for the detection of sickle hemoglobinopathies. American Journal of Hematology, 1993, 43, 110-115.	2.0	9
316	Î²-Thalassemia in Southwestern Iran. Hemoglobin, 1993, 17, 427-437.	0.4	33
317	Case Report: Effects of Iron Deficiency and the-88Câ†'T Mutation on HbA2 Levels in Î²-thalassemia. American Journal of the Medical Sciences, 1993, 305, 312-313.	0.4	7
318	Î²-Thalassemia Intermedia with Exceptionally High Hemoglobin A2: Relationship to Mutations in the Î²-Gene Promoter. American Journal of the Medical Sciences, 1992, 304, 73-78.	0.4	8
319	Laboratory profile of sickle cell disease: A cross-sectional analysis. Journal of Clinical Epidemiology, 1992, 45, 893-909.	2.4	119
320	Neonatal screening for sickle cell disease: A cost-effectiveness analysis. Journal of Pediatrics, 1991, 118, 546-554.	0.9	54
321	The Interactions of Î± -Thalassemia with Hemoglobinopathies. Hematology/Oncology Clinics of North America, 1991, 5, 453-473.	0.9	22
322	Prospects of Gene Therapy for Hemoglobinopathies. American Journal of the Medical Sciences, 1991, 302, 298-303.	0.4	1
323	Sickle cell anemia: Pathophysiology, management, and prospects for the future. Journal of Clinical Apheresis, 1991, 6, 221-223.	0.7	2
324	Hb SÎ²Â°-Thalassemia due to the Ëœ1.4-kb deletion is associated with a relatively mild phenotype. American Journal of Hematology, 1991, 38, 108-112.	2.0	23

#	Article	IF	Citations
325	Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait.. Journal of Clinical Investigation, 1991, 88, 1963-1968.	3.9	66
326	Isolation and characterization of the translation product of a Î²-globin gene nonsense mutation (Î²121) Tj ETQq0 0 0 rgBT /Overlock 10	1.2	19
327	SICKLE CELL ANAEMIA IN A SEPTUAGENARIAN. British Journal of Haematology, 1989, 71, 297-298.	1.2	5
328	Regional and temporal variation in oscillatory blood flow in sickle cell disease. American Journal of Hematology, 1988, 28, 92-94.	2.0	15
329	Review: Thalassemia: Molecular Pathology and Management. American Journal of the Medical Sciences, 1988, 296, 308-321.	0.4	6
330	HB Mississippi [Î²44(CD3)SerÃ¥G]: A New Variant with Anomalous Properties. Hemoglobin, 1987, 11, 435-452.	0.4	9
331	Screening for sickle cell trait: The veterans administration national sickle cell program. American Journal of Hematology, 1987, 24, 429-432.	2.0	10
332	Effect of Lead and Ethanol upon Î³-Globin Synthesis in Sickle Reticulocytes. American Journal of the Medical Sciences, 1986, 292, 299-305.	0.4	2
333	Influence of HbS levels upon the hematological and clinical characteristics of sickle cell trait. American Journal of Hematology, 1986, 22, 51-54.	2.0	11
334	Expression of two G-6-PD genes in an XX phenotypic male. British Journal of Haematology, 1986, 64, 107-110.	1.2	0
335	Modulation of Fetal Hemoglobin Synthesis by Iron Deficiency. New England Journal of Medicine, 1985, 313, 1402-1405.	13.9	21
336	Interaction Between HBS-Î²Â°-Tha lassemia and Î±-Thalassemia. American Journal of the Medical Sciences, 1984, 288, 195-199.	0.4	14
337	The Sickle Hemoglobinopathiesâ€"Genetic Analyses of Common Phenocopies and New Molecular Approaches to Treatment. American Journal of the Medical Sciences, 1984, 288, 169-174.	0.4	9
338	Carcinomatous Meningitis in Small Cell Lung Cancer. American Journal of the Medical Sciences, 1984, 287, 31-33.	0.4	28
339	Clinical diversity of sickle cell anemia: Genetic and cellular modulation of disease severity. American Journal of Hematology, 1983, 14, 405-416.	2.0	71
340	Spontaneous oxygen radical generation by sickle erythrocytes.. Journal of Clinical Investigation, 1982, 70, 1253-1259.	3.9	388
341	Thalassemia: Recent insights into molecular mechanisms. American Journal of Hematology, 1982, 12, 81-92.	2.0	12
342	Globin Biosynthesis in Erythroid Bursts of Heterozygous Î± or Î² Thalassaemia. British Journal of Haematology, 1981, 47, 57-65.	1.2	3

#	Article	IF	Citations
343	Effects of dexamethasone on fetal hemoglobin synthesis in peripheral blood erythroid burst-forming units. American Journal of Hematology, 1981, 10, 37-45.	2.0	9
344	Eosinophil, Eosinophilic and Eosinophilic Disorders. CRC Critical Reviews in Clinical Laboratory Sciences, 1981, 16, 35-83.	1.0	15
345	Diamond-blackfan anemia: The role of immunoglobulin blocking factor in remission. American Journal of Hematology, 1980, 8, 213-219.	2.0	2
346	Erythrocyte Adherence to Endothelium in Sickle-Cell Anemia. New England Journal of Medicine, 1980, 302, 992-995.	13.9	498
347	Multifocal Eosinophilic Granuloma. Southern Medical Journal, 1979, 72, 884-885.	0.3	2
348	Diamond-Blackfan Syndrome: Evidence for T-Cell Mediated Suppression of Erythroid Development and a Serum Blocking Factor Associated with Remission. British Journal of Haematology, 1979, 41, 57-68.	1.2	44
349	Hemoglobin Indianapolis (beta 112[G14] arginine). An unstable beta-chain variant producing the phenotype of severe beta-thalassemia.. Journal of Clinical Investigation, 1979, 63, 931-938.	3.9	87
350	Erythrocyte Calcium Abnormalities and the Clinical Severity of Sickling Disorders. British Journal of Haematology, 1978, 40, 533-539.	1.2	15
351	Laboratory Diagnosis of Sickling Hemoglobinopathies. Southern Medical Journal, 1978, 71, 413-416.	0.3	10
352	Hemoglobin F levels do not change during the painful crisis of sickle cell anemia. American Journal of Obstetrics and Gynecology, 1977, 129, 712-713.	0.7	1
353	Sickle cell anemia: Erythrokinetics, blood volumes, and a study of possible determinants of severity. American Journal of Hematology, 1977, 2, 17-23.	2.0	35
354	Alpha-thalassemia. American Journal of Hematology, 1977, 2, 317-325.	2.0	11
355	Unbalanced Globin Chain Synthesis in Erythroid Precursor Cells of Heterozygous Î±Thalassaemia. British Journal of Haematology, 1976, 34, 55-60.	1.2	6
356	Clinical, hematologic and biosynthetic studies in sickle cell-Î²Â°-thalassemia: A comparison with sickle cell anemia. American Journal of Hematology, 1976, 1, 35-44.	2.0	32
357	Alpha Thalassaemia in Adults with Sickle-Cell Trait. British Journal of Haematology, 1975, 30, 31-37.	1.2	67
358	Haemoglobin C/Î± Thalassaemia: Haematological and Biosynthetic Studies. British Journal of Haematology, 1975, 30, 337-342.	1.2	17
359	Leukocyte Alkaline Phosphatase. Annals of Internal Medicine, 1974, 81, 274.	2.0	0
360	Glucose-6-Phosphate Dehydrogenase Jackson. Acta Haematologica, 1974, 51, 310-314.	0.7	4

#	Article	IF	Citations
361	Glucose-6-Phosphate Dehydrogenase Deficiency in Sickle-Cell Anemia. Annals of Internal Medicine, 1974, 80, 217.	2.0	16
362	Chronic granulocytic leukemia. American Journal of Medicine, 1973, 55, 93-98.	0.6	18
363	Mild Sickle Cell Disease. JAMA - Journal of the American Medical Association, 1973, 224, 317.	3.8	42
364	The ultrastructure of developing bone marrow implants: A scanning electron microscope study. Cells Tissues Organs, 1973, 84, 1-9.	1.3	1
365	Electrophoresis of Hemoglobin on Polyacrylamide Gels: Precise Method for Measurement of Hemoglobin A2. Clinical Chemistry, 1973, 19, 1082-1084.	1.5	18
366	Erythrocyte glutathione peroxidase deficiency. American Journal of Medicine, 1971, 50, 542-546.	0.6	26
367	Selenite (Se75) as a tumor-scanning agent. Journal of Surgical Oncology, 1971, 3, 617-624.	0.8	7
368	Erythrocyte Glutathione-Peroxidase Deficiency. British Journal of Haematology, 1970, 19, 605-612.	1.2	57
369	Acute Hemolytic Anemia Associated With Erythrocyte Glutathione-Peroxidase Deficiency. Archives of Internal Medicine, 1970, 125, 302.	4.3	25
370	Hemoglobin SC Disease and Hemoglobin C Disorders. , 0, , 525-548.		4
371	Molecular and Cellular Basis of Hemoglobin Switching. , 0, , 86-100.		3
372	Animal Models of Hemoglobinopathies and Thalassemia. , 0, , 225-238.		0
373	Î± THALASSEMIA. , 0, , 239-240.		6
374	Hemoglobinopathies in pregnancy. , 0, , 442-468.		2
375	Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease and Î² Thalassemia. , 0, , 745-754.		6
376	Sickle Cell Pain: Biology, Etiology, and Treatment. , 0, , 497-524.		5
377	Other Sickle Hemoglobinopathies. , 0, , 564-586.		4